Literature DB >> 526000

Pharmacokinetics of cefotaxime.

K P Fu, P Aswapokee, I Ho, C Matthijssen, H C Neu.   

Abstract

The pharmacokinetics of cefotaxime after intramuscular injection and intravenous infusion were determined. The mean peak serum level after the 500-mg intramuscular dose was 11.7 micrograms/ml, and it was 20.5 micrograms/ml after a 1,000-mg dose. The serum half-life was 1.2 and 1.3 h, respectively for the two doses. The apparent fractional volumes of distribution of 32 and 37 liters were not significantly different for the two doses, and the fractional serum clearance was approximately 315 ml/min per 1.73 m2 for both doses. The mean peak serum level after 1,000 mg administered by intravenous infusion over 30 min was 41.1 micrograms/ml. The half-life was 1.13 h, apparent volume of distribution was 33 liters, serum clearance 341 ml/min per 1.73 m2, and renal clearance was 130 ml/min per 1.73 m2. The pharmacology of cefotaxime is similar to the pharmacology of other cephalosporin antibiotics, but the low inhibitory levels which it has against gram-positive and gram-negative bacteria suggest that lower dosage regimens should be possible.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526000      PMCID: PMC352911          DOI: 10.1128/AAC.16.5.592

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

3.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

4.  Comparative pharmacokinetics of cefamandole, cephapirin, and cephalothin in healthy subjects and effect of repeated dosing.

Authors:  M Barza; S Melethil; S Berger; E C Ernst
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

5.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

Review 6.  Pharmacokinetics of cephalosporin antibiotics.

Authors:  J M Brogard; F Comte; M Pinget
Journal:  Antibiot Chemother (1971)       Date:  1978

7.  Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

Authors:  R Heymès; A Lutz; E Schrinner
Journal:  Infection       Date:  1977       Impact factor: 3.553

8.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03
  8 in total
  38 in total

1.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

2.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

3.  The use of cefotaxime in the treatment of gram-positive pneumonias.

Authors:  S G Jenkinson
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.

Authors:  M Ohkawa; S Hirano; S Tokunaga; I Motoi; R Shoda; A Ikeda; T Sugata; M Sawaki; M Shimamura; A Okasho; K Kuroda
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

5.  Single 1 g dose of cefotaxime in the treatment of infections due to penicillinase-producing strains of Neisseria gonorrhoeae.

Authors:  G A de Koning; D Tio; J A van den Hoek; B van Klingeren
Journal:  Br J Vener Dis       Date:  1983-04

6.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

7.  Clinical pharmacology of cefotaxime in pediatric patients.

Authors:  D A Kafetzis; D C Brater; J Kanarios; C A Sinaniotis; C J Papadatos
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

8.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

9.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

10.  In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.

Authors:  K Oizumi; I Hayashi; S Aonuma; K Konno
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.